Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 9,445 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics Clear all
Completed Phase 1 Interventional

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

NCT00207051
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Brivanib + Cetuximab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 22, 2026, 5:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

NCT03059303
View directory record Official record
Conditions
Healthy
Interventions
Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

NCT01188603
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin 100 mg dose every evening
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Orlando, Florida • Wichita, Kansas • Kalamazoo, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 22, 2026, 5:57 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

NCT03422627
View directory record Official record
Conditions
Chronic Graft Versus Host Disease cGVHD
Interventions
Efavaleukin Alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study of Colchicine and Clarithromycin

NCT00984061
View directory record Official record
Conditions
Pharmacokinetics
Interventions
colchicine, clarithromycin
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study

NCT05447286
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NYX-783, Placebo, Oxycodone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 58 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

NCT01247194
View directory record Official record
Conditions
Chronic Genotype 1 Hepatitis C Virus Infection
Interventions
PPI-461, Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects

NCT04075175
View directory record Official record
Conditions
Diphtheria
Interventions
S315, 0.9% Sodium Chloride (NaCl)
Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional

Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

NCT06341712
View directory record Official record
Conditions
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
Interventions
Cabozantinib, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
5 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

NCT02140281
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A (cefadroxil alone), Treatment B - AZD1722 followed by cefadroxil
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Days to 50 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 22, 2026, 5:57 AM EDT
Active, not recruiting Phase 2 Interventional

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07090330
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ORKA-001 Induction Dose, Placebo, ORKA-001 Maintenance Dose
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Fountain Valley, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

NCT05277012
View directory record Official record
Conditions
Healthy Participants
Interventions
Etrumadenant
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

NCT06106828
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
San Diego, California • Danbury, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

NCT02410200
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 22, 2026, 5:57 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults

NCT01737892
View directory record Official record
Conditions
Asthma
Interventions
Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation, Arm C-Epinephrine Inhalation Aerosol CFC
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

NCT01616277
View directory record Official record
Conditions
Healthy
Interventions
PF-06252616, Placebo, PF-06252161
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 5:57 AM EDT
Completed No phase listed Observational

Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)

NCT04645667
View directory record Official record
Conditions
Acute GVHD
Interventions
Tacrolimus
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 2 Interventional

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

NCT01981837
View directory record Official record
Conditions
TTR-mediated Amyloidosis
Interventions
ALN-TTRSC (revusiran) for subcutaneous administration
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 2 Interventional

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

NCT01012375
View directory record Official record
Conditions
Adult ADHD
Interventions
AZD1446, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Los Alamitos, California • Fort Myers, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

Montelukast in Very Low Birthweight Infants

NCT00492102
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Montelukast
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Days and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

NCT02291029
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women

NCT01801475
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Ondansetron
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

NCT01436201
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Digoxin, Dulaglutide
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 22, 2026, 5:57 AM EDT